J Korean Soc Emerg Med.
2025 Feb;36(1):41-44.
Nephrogenic diabetes insipidus secondary to COVID-19 infection in a patient on lithium medication: a case report
- Affiliations
-
- 1Department of Internal Medicine, Haenam Woori General Hospital, Haenam, Korea
- 2Department of Nephrology, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Korea
Abstract
- Nephrogenic diabetes insipidus (NDI) is characterized by polyuria and polydipsia, high serum osmolality, and low urine osmolality because of resistance to antidiuretic hormone. Lithium is commonly used to treat psychiatric disorders, and NDI is one of the common renal side effects of lithium therapy. On the other hand, NDI induced by lithium medication in a patient after a coronavirus disease-19 (COVID-19) infection has not been reported. This paper presents a patient who developed new-onset NDI secondary to a COVID-19 infection despite being on a stable lithium dose for several years. This case highlights the importance of considering a COVID-19 infection as a possible cause of NDI in patients taking lithium medication.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Drug Induced Nephrogenic Diabetes Insipidus and Hyperprolactinemia in Schizophrenia Simultaneously
- A Case of Lithium-Induced Nephrogenic Diabetes Insipidus and Rhabdomyolysis
- A Case of Nephrogenic Diabetes Insipidus Associated with Hydronephrosis
- Nephrogenic Diabetes Insipidus Associated with Nonobstructive Dilation of the Urinary Tract and Voiding Difficulty
- A Case of Lithium-Induced Upper Extremity Peripheral Polyneuropathy and Nephrogenic Diabetes Insipidus
